2008 JASN IMPACT FACTOR 7.505	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by QUASCHNING, T. Articles by LÜSCHER, T. F. Search for Related Content PubMed PubMed Citation Articles by QUASCHNING, T. Articles by LÜSCHER, T. F.

Vasopeptidase Inhibition Restores Renovascular Endothelial Dysfunction in Salt-Induced Hypertension

THOMAS QUASCHNING^*, LIVIUS V. D'USCIO^*, SIDNEY SHAW, HERMANN-JOSEF GRÖNE, FRANK RUSCHITZKA and THOMAS F. LÜSCHER

^* Cardiovascular Research, Institute of Physiology, University of Zürich, Zürich, Switzerland
Clinical Research, Inselspital, University of Bern, Bern, Switzerland
Cellular and Molecular Pathology, German Cancer Research Center, Heidelberg, Germany
Cardiovascular Center and Cardiology, University of Zürich, Zürich, Switzerland.

Correspondence to Dr. Thomas F. Lüscher, Professor and Head of Cardiology, University Hospital, CH-8091 Zürich, Switzerland. Phone: 0041 1 255 21 21; Fax: 0041 1 255 42 51; E-mail: cardiotfl{at}gmx.de

Abstract. Renovascular hemodynamics plays a pivotal role in the regulation of BP. The effect of the vasopeptidase inhibitor omapatrilat (O) and the ACE-inhibitor captopril (C) on endothelial function in the renal circulation in salt-induced hypertension were investigated. Dahl salt-sensitive rats (n = 6 per group) on standard or salt-enriched chow were treated for 8 wk with O (36 ± 4 mg/kg per d), C (94 ± 2 mg/kg per d), or placebo. Renal arteries were suspended in organ chambers for isometric tension recording. Vascular hypertrophy was assessed by determination of standardized heart weight and aortic weight, and morphologic analysis of glomerular injury was performed. Systolic BP of salt-fed, placebo-treated animals increased to 196 ± 6 mmHg, which was reduced by O (162 ± 5 mmHg; P < 0.05) and C (164 ± 7 mmHg; P < 0.05) to a comparable degree. In salt-induced hypertension, endothelium-dependent relaxations in renal arteries (56 ± 6 versus 100 ± 6%; P < 0.05) as well as contractions to endothelin-1 (ET-1) (98 ± 5% versus 128 ± 5%; P < 0.05) and big ET-1 (47 ± 6% versus 116 ± 7%; P < 0.05) were markedly reduced as compared with control animals, whereas standardized aortic weight and heart weight (4.9 ± 0.4 versus 3.2 ± 0.3 g/kg; P < 0.05) increased. Treatment with O restored endothelium-dependent relaxations (88 ± 6%; P < 0.05 versus C) and contractions to ET-1 (120 ± 6%) and big ET-1 (98 ± 9%). O prevented vascular hypertrophy (0.23 ± 0.019 mg/mm² versus 0.31 ± 0.018 mg/mm² in high-salt diet; P < 0.05), but, in contrast to C, it only had a modest effect on glomerular injury. In conclusion, O restored renovascular endothelial function and prevented vascular hypertrophy in salt-induced hypertension and therefore may advance as a beneficial approach in the therapy of various forms of hypertension.

This article has been cited by other articles:

				E. P. Davidson, T. L. Kleinschmidt, C. L. Oltman, D. D. Lund, and M. A. Yorek Treatment of Streptozotocin-Induced Diabetic Rats With AVE7688, a Vasopeptidase Inhibitor: Effect on Vascular and Neural Disease Diabetes, February 1, 2007; 56(2): 355 - 362. [Abstract] [Full Text] [PDF]

				W. Linz, S. Schafer, F. Afkham, M. Gerl, H.-L. Schmidts, and H. Rutten Vasopeptidase Inhibition Prevents Target Organ Damage and Improves Survival in Spontaneously Hypertensive Rats Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 155 - 161. [Abstract] [PDF]

				M. Hermann, S. Shaw, E. Kiss, G. Camici, N. Buhler, R. Chenevard, T. F. Luscher, H. J. Grone, and F. Ruschitzka Selective COX-2 Inhibitors and Renal Injury in Salt-Sensitive Hypertension Hypertension, February 1, 2005; 45(2): 193 - 197. [Abstract] [Full Text] [PDF]

				S. Garwood Renal Insufficiency After Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2004; 8(3): 227 - 241. [Abstract] [PDF]

				A. W. Cowley Jr, R. J. Roman, and H. J. Jacob Application of chromosomal substitution techniques in gene-function discovery J. Physiol., January 1, 2004; 554(1): 46 - 55. [Abstract] [Full Text] [PDF]

				S. Schafer, W. Linz, A. Bube, M. Gerl, J. Huber, G. U. Kurzel, M. Bleich, H.-L. Schmidts, A. E Busch, and H. Rutten Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats Cardiovasc Res, November 1, 2003; 60(2): 447 - 454. [Abstract] [Full Text] [PDF]

				L. Ying, M. Flamant, S. Vandermeersch, J.-J. Boffa, C. Chatziantoniou, J.-C. Dussaule, and D. Chansel Renal Effects of Omapatrilat and Captopril in Salt-Loaded, Nitric Oxide-Deficient Rats Hypertension, November 1, 2003; 42(5): 937 - 944. [Abstract] [Full Text] [PDF]

				U. O. Wenzel, G. Wolf, I. Jacob, C. Schwegler, A. Qasqas, K. Amann, U. Helmchen, and R. A. K. Stahl Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2005 - 2013. [Abstract] [Full Text] [PDF]

Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673